Bulletin campaigns against withdrawal of Mixtard 30BMJ 2010; 341 doi: http://dx.doi.org/10.1136/bmj.c4210 (Published 04 August 2010) Cite this as: BMJ 2010;341:c4210
- Nigel Hawkes
A campaign has been launched against the decision by the Danish drug company Novo Nordisk to withdraw a form of insulin used by 90 000 patients in the United Kingdom.
Mixtard 30, which is a 30:70 mixture of short acting and intermediate acting human insulin, is to be withdrawn from the market at the end of the year. Novo Nordisk’s decision, announced in June, caused disquiet among doctors and diabetes charities. Douglas Smallwood, chief executive of Diabetes UK, said at the time that he was “very disappointed” by the announcement and had sought unsuccessfully to have it reversed.
Ike Iheanacho, editor of the Drug and Therapeutics Bulletin (a BMJ Group publication), said that …
Log in using your username and password
Log in through your institution
Sign up for a free trial